Life sciences distribution is shifting toward AI-powered, resilient networks that improve speed, efficiency, compliance, and ...

Once overlooked as the merely the human body’s plumbing, the lymphatic system is emerging as a new therapeutic frontier, ...

On this weeks episode of the Business of Biotech, Bret Bostwick, M.D., Venture Partner at Breyer Capital, a family office, talks about his path from medical geneticist to CNS drug development and ...

Industry Explorers Blaze On: A series of stories of longtime leaders, still active in the industry, sharing their historical perspectives on life sciences industry innovation. A consuming interest, ...

In the United States, it has typically taken 10 to 15 years for breakthrough research to be adopted in real-world clinical settings: a decade or more between proving something saves lives and actually ...

Managing third-party risk is one of the most arduous challenges facing pharmaceutical companies, and regulatory requirements are just one piece of this puzzle. Pharmaceutical organizations are ...

Why did John Oyler, an American entrepreneur, decide to build a global biopharmaceutical company with roots in China? Ask the chairman, cofounder, and CEO of BeiGene that question and you’re going to ...

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.

Life sciences companies operate at the leading edge of innovation, structuring high-value licensing, development, and outsourcing arrangements in a highly regulated environment. A persistent and often ...

Professor Ugur Sahin, M.D., Ph.D. never wanted to be an entrepreneur. Yet, today he’s the cofounder and CEO of BioNTech, a publicly traded German biotech aspiring to develop individualized cancer ...

Achieving regulatory approval for a new drug is an extraordinary achievement. The bar for success is high. Many companies with breakthrough scientific discoveries and promising clinical data still ...

Speed alone no longer guarantees success; here’s what matters most in today’s launch environment. In today’s launch environment, order of entry (OOE) isn’t destiny. Many brands still anchor strategy ...